BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26028064)

  • 1. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
    Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
    Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of genomic changes on treatment of lung cancer.
    Cardarella S; Johnson BE
    Am J Respir Crit Care Med; 2013 Oct; 188(7):770-5. PubMed ID: 23841470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Going beyond EGFR.
    Zimmermann S; Peters S
    Ann Oncol; 2012 Sep; 23 Suppl 10():x197-203. PubMed ID: 22987962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted/emerging therapies for metastatic non-small cell lung cancer.
    Horn L
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):676-8. PubMed ID: 25995428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
    Lambros L; Guibourg B; Uguen A
    Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
    [No Abstract]   [Full Text] [Related]  

  • 6. Personalized targeted therapy for lung cancer.
    Wu K; House L; Liu W; Cho WCS
    Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in systemic treatment for lung cancer.
    Clark JW; Longo DL
    Curr Opin Pulm Med; 2018 Jul; 24(4):355-366. PubMed ID: 29697418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting
    Baik CS; Myall NJ; Wakelee HA
    Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F; Lautenschlaeger T
    Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targets in the treatment of non-small-cell lung cancer: is there hope on the horizon?
    Carter CA; Nations JA; Lazarus A
    Postgrad Med; 2014 Nov; 126(7):139-48. PubMed ID: 25387222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
    Gou Q; Gou Q; Gan X; Xie Y
    Sci Rep; 2024 May; 14(1):10317. PubMed ID: 38705930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targets and new mechanisms in lung cancer.
    Carrizosa DR; Mileham KF; Haggstrom DE
    Oncology (Williston Park); 2013 May; 27(5):396-404. PubMed ID: 25184262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
    Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
    Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic targets in non-small cell lung cancer.
    Alamgeer M; Ganju V; Watkins DN
    Curr Opin Pharmacol; 2013 Jun; 13(3):394-401. PubMed ID: 23608109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular markers as therapeutic targets in lung cancer.
    Tseng HH; He B
    Chin J Cancer; 2013 Feb; 32(2):59-62. PubMed ID: 23369726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.